CorePath Laboratories Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CorePath Laboratories's estimated annual revenue is currently $13.4M per year.(i)
  • CorePath Laboratories's estimated revenue per employee is $243,000

Employee Data

  • CorePath Laboratories has 55 Employees.(i)
  • CorePath Laboratories grew their employee count by 25% last year.

CorePath Laboratories's People

NameTitleEmail/Phone
1
EVP Business OperationsReveal Email/Phone
2
President and Medical DirectorReveal Email/Phone
3
Director Laboratory DevelopmentReveal Email/Phone
4
President and Medical DirectorReveal Email/Phone
5
Technical Director, Molecular Diagnostics LaboratoryReveal Email/Phone
6
Quality Assurance ManagerReveal Email/Phone
7
BioPharma ManagerReveal Email/Phone
8
Sales SpecialistReveal Email/Phone
9
Medical Technologist Flow CytometryReveal Email/Phone
10
PathologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.9M32-9%N/AN/A
#2
$8.6M40-13%N/AN/A
#3
$10.4M4817%N/AN/A
#4
$42.2M14214%N/AN/A
#5
$10.6M4926%N/AN/A
#6
$8M376%N/AN/A
#7
$4M21-5%N/AN/A
#8
$8.9M41-7%N/AN/A
#9
$10.8M500%N/AN/A
#10
$8M37-24%N/AN/A
Add Company

What Is CorePath Laboratories?

Founded in San Antonio, Texas as one of the few international laboratories with the ability to offer cancer cytogenetics, molecular genetics and multicolor flow cytometry services at one location, CorePath brings academic expertise, compassion and state of the art technology to help physicians help their patients and achieve the most accurate time-sensitive results for early treatment. Together, we are a highly-specialized team with a shared passion: “Caring for Lives.” We are a proud recipient of the 2019 Top Workplaces in San Antonio Award.

keywords:N/A

N/A

Total Funding

55

Number of Employees

$13.4M

Revenue (est)

25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.2M5512%N/A
#2
$5M5520%N/A
#3
N/A5534%N/A
#4
$16.3M5534%N/A
#5
$10.9M558%N/A